Curevac announces financial results for the second quarter and first half of 2025 and provides business updates

Curevac announces financial results for the second quarter and first half of 2025 and provides business updates entered into a definitive purchase agreement pursuant to which biontech intends to acquire all shares of curevac, uniting two highly complementary german companies to bring transformative mrna-based treatments to patients globally entered into agreements to resolve and dismiss all pending patent litigation in the u.s. with pfizer/biontech related to mrna-based covid-19 vaccines and to set a framework for resolving related ongoing patent disputes outside the u.s. upon closing of biontech's acquisition of curevac received clinical trial application (cta) clearance from the european medicines agency (ema) for cvhnlc, a proprietary off-the-shelf cancer immunotherapy candidate targeting squamous non-small cell lung cancer (sqnsclc) cvgbm glioblastomadata from part b of phase 1 remain on track for h2 2025 strong cash and cash equivalents position of €392.7 million as of june 30, 2025; expected cash runway into 2028 tÜbingen, germany and boston, ma / access newswire / august 15, 2025 / curevac n.v. (nasdaq:cvac), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger rna (mrna), today announced financial results for the second quarter and first half of 2025 and provided a business update.
CVAC Ratings Summary
CVAC Quant Ranking